Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of “Buy” by Brokerages

Immunic, Inc. (NASDAQ:IMUX) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $6.00.

Several research firms have issued reports on IMUX. HC Wainwright decreased their price target on shares of Immunic from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. D. Boral Capital reduced their target price on shares of Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Finally, raised Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd.

Institutional Trading of Immunic

Several institutional investors have recently modified their holdings of IMUX. Nantahala Capital Management LLC bought a new stake in shares of Immunic during the fourth quarter valued at approximately $2,337,000. Millennium Management LLC lifted its position in Immunic by 544.6% in the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock worth $1,825,000 after purchasing an additional 2,888,829 shares during the period. Laurion Capital Management LP boosted its stake in Immunic by 106.3% during the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after buying an additional 2,000,000 shares in the last quarter. Marshall Wace LLP boosted its stake in Immunic by 91.2% during the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock worth $541,000 after buying an additional 486,468 shares in the last quarter. Finally, Connective Capital Management LLC bought a new stake in Immunic in the 4th quarter valued at $161,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Trading Down 5.2%

IMUX opened at $1.10 on Monday. The business has a 50 day moving average of $0.88 and a 200-day moving average of $0.79. The stock has a market capitalization of $143.51 million, a price-to-earnings ratio of -1.57 and a beta of 1.45. Immunic has a 1-year low of $0.51 and a 1-year high of $1.51.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities analysts predict that Immunic will post -0.94 EPS for the current year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.